Ani pharmaceuticals announces launch of prazosin hydrochloride (“hcl”) capsules

Baudette, minn.--(business wire)--ani pharmaceuticals, inc. (“ani” or the “company”) (nasdaq: anip) today announced the launch of prazosin hcl capsules usp, 1mg and 2mg, following the u.s. food and drug administration's (“fda”) approval of the company's prior approval supplement application (“pas”). the current annual u.s. market for prazosin 1mg and 2mg strengths is approximately $46.2 million, according to iqvia/ims health. "launch of prazosin hcl is ani's fourteenth re-commercialization of a
ANIP Ratings Summary
ANIP Quant Ranking